Kiniksa files Form 144 for 6,625 Class A shares

Kiniksa Pharmaceuticals International, plc filed a Form 144 reporting proposed dispositions of Class A ordinary shares.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc filed a Form 144 reporting proposed dispositions of Class A ordinary shares. The filing lists a total of 6,625 shares tied to restricted stock lapses on 04/01/2026 (4,359 shares) and 04/07/2026 (2,266 shares).

Insights

Securities Counsel

Form 144 notice lists proposed sales after restricted stock lapses totaling 6,625 Class A shares.

The filing is administrative: it notifies the market under Rule 144 of proposed sales connected to equity compensation vesting on 04/01/2026 and 04/07/2026. The listed counts are 4,359 and 2,266 shares respectively.

Cash‑flow treatment and purchaser details are not shown in the excerpt; subsequent Form 4 or transaction reports would show actual sales if they occur.

Key Figures

Total shares listed: 6,625 shares Restricted stock lapse: 4,359 shares Restricted stock lapse: 2,266 shares +1 more

4 metrics

Total shares listed 6,625 shares aggregate of listed dispositions in the excerpt

Restricted stock lapse 4,359 shares lapse date <date>04/01/2026</date>

Restricted stock lapse 2,266 shares lapse date <date>04/07/2026</date>

Form date / listing reference 04/09/2026 date shown near NASDAQ entry in excerpt

Key Terms

Form 144, Class A ordinary shares, Restricted Stock Lapse

3 terms

Form 144 regulatory

"Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Class A ordinary shares market

"Class A ordinary shares | Charles Schwab & Co., Inc."

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

Restricted Stock Lapse financial

"04/01/2026 | Restricted Stock Lapse | Kiniksa Pharmaceuticals International, plc"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Form 144 disclose about shares being sold?

It discloses proposed dispositions of Class A ordinary shares totaling 6,625 shares. The filing lists 4,359 shares from 04/01/2026 and 2,266 shares from 04/07/2026 tied to restricted stock lapses.

Does the Form 144 show when the restricted stock lapsed for KNSA?

Yes. The filing shows restricted stock lapses on 04/01/2026 and 04/07/2026. Those dates correspond to the 4,359 and 2,266 share entries noted in the Form 144 excerpt.

Are the proposed sales on Form 144 already completed for KNSA?

No. Form 144 is a notice of proposed sales under Rule 144, not proof of completion. The excerpt lists proposed dispositions; completion would be reflected in later transaction reports if sales occur.

Which security class is referenced in the KNSA Form 144?

The filing references Class A ordinary shares. Each listed disposition line in the excerpt is tied to that share class and to equity compensation-related restricted stock lapses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 04:02 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001464583
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Megna Michael R
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	6625	309321.00	45900637	04/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	04/01/2026	Restricted Stock Lapse	Kiniksa Pharmaceuticals International, plc			4359	04/01/2026	Equity Compensation
Class A ordinary shares	04/07/2026	Restricted Stock Lapse	Kiniksa Pharmaceuticals International, plc			2266	04/07/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	04/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/24/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Michael R Megna
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)